Skip to content

Asset turnover at other companies

CG Oncology logo
CG OncologyCGON
0.0×
Arrowhead Research logo
Arrowhead ResearchARWR
0.3×-0.1×
BridgeBio Pharma logo
BridgeBio PharmaBBIO
0.5×+0.4×
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
0.3×0.0×
Spyre Therapeutics, Inc. logo
Spyre Therapeutics, Inc.SYRE
Revvity logo
RevvityRVTY
0.2×0.0×

Other financials

Income statement

See full
Revenue$1.5M+68.6%
Operating income-$130.2M+12.2%
Net income-$122.9M+9.6%
EPS (diluted)-$1.28+19.0%

Balance sheet

See full
Cash & equivalents$423.3M+80.0%
Total debt$787.6M+259%
Total equity$1.8B-0.8%
Total assets$2.7B+25.8%

Cash flow

See full
Operating cash flow-$108.9M-102%
CapEx$504.0K+145%
Free cash flow-$109.4M-102%

Valuation

See full
Market cap$5.33B+56.4%
Enterprise value$5.69B+69.8%
P/S1,298.3×+1,208×

Profitability

See full
Operating margin-15,754.2%-17,253pp
Net margin-13,856.5%-15,058pp
FCF margin-9,777.6%-10,759pp

Returns & leverage

See full
Return on equity-31.2%+43.7pp
Debt / equity0.4×+0.3×
Current ratio18×+2.3×

Where this comes from

Calculated from CRISPR Therapeutics’s reported figures.

Based on trailing twelve months.

The official record: CRISPR Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about CRISPR Therapeutics's asset turnover.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CRISPR Therapeutics's asset turnover?
CRISPR Therapeutics (CRSP) reported asset turnover of 0× in Q1 2026.
How has CRISPR Therapeutics's asset turnover changed year-over-year?
CRISPR Therapeutics's asset turnover decreased by 89.6% year-over-year, from 0× to 0×.
What is the long-term trend for CRISPR Therapeutics's asset turnover?
Over 5 years (2020 to 2025), CRISPR Therapeutics's asset turnover has grown at a 26.2% compound annual growth rate (CAGR), from 0× to 0×.
What does asset turnover mean?
Trailing-twelve-month revenue divided by average total assets. Measures how many dollars of sales each dollar of assets generates — the efficiency leg of the DuPont decomposition of ROE.